Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-12-2005 | Original Article

Image fusion analysis of ^99mTc-HYNIC-Tyr³-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours

Authors: Michael Gabriel, Florian Hausler, Reto Bale, Roy Moncayo, Clemens Decristoforo, Peter Kovacs, Irene Virgolini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2005

Abstract

Purpose

The aim of this study was to assess the value of multimodality imaging using a novel repositioning device with external markers for fusion of single-photon emission computed tomography (SPECT) and computed tomography (CT) images. The additional benefit derived from this methodological approach was analysed in comparison with SPECT and diagnostic CT alone in terms of detection rate, reliability and anatomical assignment of abnormal findings with SPECT.

Methods

Fifty-three patients (30 males, 23 females) with known or suspected endocrine tumours were studied. Clinical indications for somatostatin receptor (SSTR) scintigraphy (SPECT/CT image fusion) included staging of newly diagnosed tumours (n=14) and detection of unknown primary tumour in the presence of clinical and/or biochemical suspicion of neuroendocrine malignancy (n=20). Follow-up studies after therapy were performed in 19 patients. A mean activity of 400 MBq of ^99mTc-EDDA/HYNIC-Tyr³-octreotide was given intravenously. SPECT using a dual-detector scintillation camera and diagnostic multi-detector CT were sequentially performed. To ensure reproducible positioning, patients were fixed in an individualised vacuum mattress with modality-specific external markers for co-registration. SPECT and CT data were initially interpreted separately and the fused images were interpreted jointly in consensus by nuclear medicine and diagnostic radiology physicians.

Results

SPECT was true-positive (TP) in 18 patients, true-negative (TN) in 16, false-negative (FN) in ten and false-positive (FP) in nine; CT was TP in 18 patients, TN in 21, FP in ten and FN in four. With image fusion (SPECT and CT), the scan result was TP in 27 patients (50.9%), TN in 25 patients (47.2%) and FN in one patient, this FN result being caused by multiple small liver metastases; sensitivity was 95% and specificity, 100%. The difference between SPECT and SPECT/CT was statistically as significant as the difference between CT and SPECT/CT image fusion (P<0.001). Twenty-seven abnormal SPECT findings in 17 patients could not be initially assigned to organs, but were clearly delineated after image fusion. In 21 patients (40%), clinically relevant information was obtained by image fusion as compared with SPECT alone.

Conclusion

Co-registration of SPECT and diagnostic CT using a cost-effective immobilisation device provides excellent accuracy for tumour detection of endocrine malignancies and is superior to SPECT and CT alone. Image fusion reduces false positive results and can detect additional lesions. Anatomical information provided by CT enables precise localisation of abnormalities observed in SPECT.

Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of ^99mTc-EDDA/HYNIC-TOC with ¹¹¹In-DTPA-octreotide for diagnosis of somatostatin receptor expressing tumors. J Nucl Med 2003;44:708–16PubMed

Gabriel M, Muehllechner P, Decristoforo C, et al.^99mTc-EDDA/HYNIC-Tyr³-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging 2005;in press

Weber DA, Ivanovic M. Correlative image registration. Semin Nucl Med 1994;24:311–23PubMed

Perault C, Schvartz C, Wampach H, Liehn JC, Delisle MJ. Thoracic abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. J Nucl Med 1997;38:1234–42PubMed

Amthauer H, Ruf J, Bohmig M, Lopez-Hanninen E, Rohlfing T, Wernecke KD, et al. Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit? Eur J Nucl Med Mol Imaging 2004;31:342–8CrossRefPubMed

Even-Sapir E, Keidar Z, Sachs J, Engel A, Bettman L, Gaitini D, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med 2001;42:998–1004PubMed

Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Vonthein R, Claussen CD, et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 2003;30:835–43PubMed

Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with¹¹¹In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59:565–73CrossRef

Schillaci O. Functional-anatomical image fusion in neuroendocrine tumors. Cancer Biother Radiopharm 2004;19:129–34CrossRefPubMed

10.

Schillaci O, Danieli R, Manni C, Simonetti G. Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation? Nucl Med Common 2004;25:705–10CrossRef

11.

Forster GJ, Laumann C, Nickel O, Kann P, Rieker O, Bartenstein P. SPET/CT image co-registration in the abdomen with a simple and cost-effective tool. Eur J Nucl Med Mol Imaging 2003;30:32–9CrossRefPubMed

12.

Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ.^99mTc-HYNIC-[Tyr³]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with¹¹¹In-octreotide. J Nucl Med 2000;41:1114–9PubMed

13.

Von Guggenber E, Mikolajczak R, Janota B, Riccabona G, Decristoforo C. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [^99mTc-EDDA-HYNIC-D-Phe¹,Tyr³]-octreotide, a somatostatin analog for tumor diagnosis. J Pharm Sci 2004;93:2497–506CrossRefPubMed

14.

Ozer S, Dobrozemsky G, Kienast O, Beheshti M, Becherer A, Niederle B, et al. Value of combined XCT/SPET technology for avoiding false positive planar¹²³I-MIBG scintigraphy. Nuklearmediziner 2004;43:164–70

15.

Horger M, Eschmann SM, Pfannenberg C, Storek D, Dammann F, Vonthein R, et al. The value of SPET/CT in chronic osteomyelitis. Eur J Nucl Med Mol Imaging 2003;30:1665–73CrossRefPubMed

16.

Amthauer H, Denecke T, Rohlfing T, Ruf J, Bohmig M, Gutberlet M, et al. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with retrospective voxel-based method in neuroendocrine tumours. Eur Radiol 2005;15:1456–62CrossRefPubMed

17.

Sweeney RA, Bale RJ, Moncayo R, Seydl K, Trieb T, Eisner W, et al. Multimodality cranial image fusion using external markers applied via a vacuum mouthpiece and a case report. Strahlenther Onkol 2003;179:254–60CrossRefPubMed

18.

Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with⁹⁰Y-labelled somatostatin analogs. J Nucl Med 2005;46:92S–8SPubMed

19.

De Juan R, Seifert B, Berthold T, Von Schulthess GK, Goerres GW. Clinical evaluation of a breathing protocol for PET/CT. Eur Radiol 2004;14:1118–23CrossRefPubMed

20.

Schillaci O. Hybrid SPECT/CT: a new era for SPECT. Eur J Nucl Med Mol Imaging 2005;32:521–4CrossRefPubMed

21.

Cholewinski W, Decristoforo C, Mather SJ, Donnemiller E, Gabriel M, Moncayo R. Biokinetics and dosimetry of^99mTc-HYNIC/EDDA-octreotide in tumour patients. Eur J Nucl Med Mol Imaging 2002;29:S656

22.

Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R.^99mTc-EDDA/HYNIC-TOC: a new^99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with¹¹¹In-labelled octreotide derivates. Eur J Nucl Med 2000;27:1318–25CrossRefPubMed

Title: Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours
Authors: Michael Gabriel
Florian Hausler
Reto Bale
Roy Moncayo
Clemens Decristoforo
Peter Kovacs
Irene Virgolini
Publication date: 01-12-2005
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2005
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-1875-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Image fusion analysis of ^99mTc-HYNIC-Tyr³-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2005

Small cell lung carcinoma invading the pulmonary vein and left atrium as imaged by PET/CT

Nuclear cardiology and correlative imaging: a teaching file. 2004. J.V. Vitola and D. Delbeke (Eds). Springer, Berlin Heidelberg New York. 630 figs. 490 pp. Hardcover. Price € 149.95, SFR 254.00, GBP 115.50, US $ 149.00. ISBN 0-387-20707-4

A comparison of PET imaging characteristics of various copper radioisotopes

Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer

Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent

The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease